Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01138618
NCT01138618
Completed
Not Applicable

Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)

University of Aarhus6 sites in 1 country85 target enrollmentApril 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSchizophrenia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
University of Aarhus
Enrollment
85
Locations
6
Primary Endpoint
Pain sensation
Status
Completed
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Clozapine remain the drug of choice for treatment resistant schizophrenia and up to 60% of patients not responding to other antipsychotics will respond to clozapine. However, the use of clozapine is restricted due to the risk of agranulocytosis and consequently the need for mandatory hematological monitoring. CHEMPAQ XBC is a point-of-care device that can be used in patients home and analyze WBC and granulocytes by a single capillary blood drop. This study aims to investigate whether this new procedure increases the acceptability of clozapine

Registry
clinicaltrials.gov
Start Date
April 2010
End Date
May 2011
Last Updated
14 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Treated with clozapine
  • •Compliant with blood monitoring
  • •Willing to give informed consent

Exclusion Criteria

  • •Prior case of agranulocytosis

Outcomes

Primary Outcomes

Pain sensation

Time Frame: Monthly for four months

Pain sensation was measured using a visual analog scale (VAS)

Secondary Outcomes

  • The benefits of CHEMPAQ(Monthly for four months)

Study Sites (6)

Loading locations...

Similar Trials

Completed
Phase 4
Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic PatientsSchizophrenia
NCT01663077Tirat Carmel Mental Health Center20
Completed
Not Applicable
Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)Schizophrenia
NCT02404155University of Maryland, Baltimore274
Completed
Not Applicable
Prevalence of Sialorrhea in Patients Treated With ClozapineSialorrheaClozapine Adverse ReactionQuality of Life
NCT04197037Parc de Salut Mar129
Completed
Not Applicable
Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)Schizophrenia
NCT00753051Khon Kaen University18
Completed
Phase 4
Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and FluvoxamineSchizophrenia
NCT01401491Taipei Medical University Hospital80